0 14 Pentoxifylline Pentoxifylline NNP 15 18 for for IN 19 22 the the DT 23 32 treatment treatment NN 33 35 of of IN 36 45 infection infection NN 46 50 with with IN 51 56 human human JJ 57 73 immunodeficiency immunodeficiency NN 74 79 virus virus NN 79 80 . . . 82 90 Cytokine Cytokine NNP 91 104 dysregulation dysregulation NN 105 107 in in IN 108 113 human human JJ 114 130 immunodeficiency immunodeficiency NN 131 136 virus virus NN 137 141 type type NN 142 143 1 1 CD 144 145 ( ( ( 145 150 HIV-1 HIV-1 NNP 150 151 ) ) ) 152 161 infection infection NN 162 165 has have VBZ 166 170 been be VBN 171 181 documented document VBN 182 184 in in IN 185 193 numerous numerous JJ 194 201 studies study NNS 202 205 and and CC 206 209 has have VBZ 210 214 been be VBN 215 220 cited cite VBN 221 223 as as IN 224 226 an an DT 227 236 important important JJ 237 246 component component NN 247 249 in in IN 250 253 the the DT 254 266 pathogenesis pathogenesis NN 267 269 of of IN 270 274 this this DT 275 285 retroviral retroviral JJ 286 295 infection infection NN 295 296 . . . 297 312 Pharmacological pharmacological JJ 313 325 modification modification NN 326 328 of of IN 329 337 cytokine cytokine NN 338 351 dysregulation dysregulation NN 351 352 , , , 353 362 therefore therefore RB 362 363 , , , 364 367 has have VBZ 368 372 been be VBN 373 382 suggested suggest VBN 383 385 as as IN 386 387 a a DT 388 399 therapeutic therapeutic JJ 400 408 modality modality NN 409 412 for for IN 413 418 HIV-1 HIV-1 NNP 419 428 infection infection NN 428 429 . . . 430 433 Dr. Dr. NNP 434 440 Dezube Dezube NNP 441 443 of of IN 444 448 Beth Beth NNP 449 455 Israel Israel NNP 456 464 Hospital Hospital NNP 465 466 ( ( ( 466 472 Boston Boston NNP 472 473 ) ) ) 474 483 concisely concisely RB 484 491 reviews review VBZ 492 495 the the DT 496 501 state state NN 502 504 of of IN 505 508 our our PRP$ 509 518 knowledge knowledge NN 519 528 regarding regard VBG 529 532 the the DT 533 540 effects effect NNS 541 543 of of IN 544 558 pentoxifylline pentoxifylline NN 559 561 on on IN 562 572 expression expression NN 573 575 of of IN 576 581 tumor tumor NN 582 590 necrosis necrosis NN 591 603 factor-alpha factor-alpha NN 603 604 , , , 605 606 a a DT 607 615 cytokine cytokine NN 616 621 known know VBN 622 624 to to TO 625 634 influence influence VB 635 640 HIV-1 HIV-1 NNP 641 652 replication replication NN 653 656 and and CC 657 659 to to TO 660 664 play play VB 665 666 a a DT 667 675 possible possible JJ 676 680 role role NN 681 683 in in IN 684 687 the the DT 688 696 clinical clinical JJ 697 711 manifestations manifestation NNS 712 714 of of IN 715 723 advanced advanced JJ 724 733 infection infection NN 734 738 with with IN 739 743 this this DT 744 749 virus virus NN 749 750 . . . 751 765 Pentoxifylline Pentoxifylline NNP 765 766 , , , 767 768 a a DT 769 783 trisubstituted trisubstitute VBN 784 792 xanthine xanthine NN 793 803 derivative derivative NN 803 804 , , , 805 808 has have VBZ 809 813 been be VBN 814 818 used use VBN 819 821 to to TO 822 830 decrease decrease VB 831 836 blood blood NN 837 846 viscosity viscosity NN 847 850 and and CC 851 853 is be VBZ 854 864 reasonably reasonably RB 865 869 well well RB 870 879 tolerated tolerate VBN 880 882 by by IN 883 887 most most JJS 888 898 recipients recipient NNS 899 901 of of IN 902 905 the the DT 906 910 drug drug NN 910 911 . . . 912 919 Results result NNS 920 922 of of IN 923 934 preliminary preliminary JJ 935 942 studies study NNS 942 943 , , , 944 948 many many JJ 949 951 of of IN 952 957 which which WDT 958 962 were be VBD 963 972 conducted conduct VBN 973 975 by by IN 976 979 Dr. Dr. NNP 980 986 Dezube Dezube NNP 986 987 , , , 988 995 suggest suggest VBP 996 1000 that that IN 1001 1004 use use NN 1005 1007 of of IN 1008 1012 this this DT 1013 1018 agent agent NN 1019 1021 in in IN 1022 1033 combination combination NN 1034 1038 with with IN 1039 1053 antiretroviral antiretroviral JJ 1054 1063 compounds compound NNS 1064 1067 may may MD 1068 1073 prove prove VB 1074 1080 useful useful JJ 1081 1083 in in IN 1084 1087 the the DT 1088 1097 treatment treatment NN 1098 1100 of of IN 1101 1109 patients patient NNS 1110 1114 with with IN 1115 1120 HIV-1 HIV-1 NNP 1121 1130 infection infection NN 1130 1131 . . .